TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

Francesco Manfredi(University of Zurich), Eliana Ruggiero(Vita-Salute San Raffaele University)
Frontiers in Immunology
September 3, 2020
10.3389/fimmu.2020.01689
Cited by 101

Related Papers

TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength
|Nature Communications|2026|2
Abstract 5: Cytosine base editor ameliorates the safety profile of TCR edited T cells for the adoptive cell therapy of gastrointestinal tumors
|Cancer Research|2024|0
Abstract LB029: TIGIT deletion rescues the antitumor activity of low avidity T cells by increasing TCR signal strength
|Cancer Research|2025|0